Compare Adaptive Biotechnologies Corp (ADPT) vs Jabil Inc (JBL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Jabil Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while Jabil Inc trades at $320.53 (market cap $33.65B). The key difference: Jabil Inc is far larger — about 10.1× Adaptive Biotechnologies Corp's market cap, and Jabil Inc pays a 0.1% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | JBL | |
|---|---|---|
Market Cap | $3.33B | $33.65B |
Sector | Health | Technology |
52-Week High | $22.37 | $385.50 |
52-Week Low | $10.24 | $192.49 |
Enterprise Value | $3.19B | $36.18B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
JBL trades at $338.22, down 0.9% today, with technical indicators showing a bearish trend near support at $333. The stock has demonstrated strong earnings momentum, beating estimates for three consecutive quarters, and benefits from AI infrastructure demand driving revenue growth. Analyst consensus is split evenly between Buy and Hold ratings with a $436.50 price target suggesting significant upside potential.
The outlook remains positive due to AI-driven growth and margin expansion, though high valuation multiples and competitive pressures present risks. Recent manufacturing expansion in India and hyperscaler customer wins support long-term growth, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
